Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community

Zoledronic Acid (Zometa) for the Management of Tumor-induced Hypercalcemia (TIH) and Malignant Bone Pain (MBP) in the Community: A Feasibility Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00126386

Enrollment

Registered

2005-08-04

Start date

2004-01-31

Completion date

2006-09-30

Last updated

2011-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Hypercalcemia, Pain

Keywords

tumor induced hypercalcemia, malignant bone pain, bisphosphonates, cancer, palliative, Zometa, palliative patient, treatment in community

Brief summary

Treatment in the home and hospice of long-term care facilities, particularly for non-ambulatory patients, could provide significant advantages for patients and for the region. The Calgary Health Region has a unique resource in the home parenteral therapy program (HPTP). With the assistance of HPTP, patients requiring bisphosphonate treatment for the management of tumor-induced hypercalcemia (TIH) or malignant bone pain (MBP) could be treated in the community (ie at home). However, the resources required and the costs associated with community-based (homes, hospices, long-term care facilities) treatment of TIH and MBP need to be identified and evaluated so as to guide future regional decision making.

Detailed description

Treatment in the home and hospice of long-term care facilities, particularly for non-ambulatory patients, could provide significant advantages for patients and for the region. The Calgary Health Region has a unique resource in the home parenteral therapy program (HPTP). With the assistance of HPTP, patients requiring bisphosphonate treatment for the management of TIH or MBP could be treated in the community (ie at home). However, the resources required and the costs associated with community-based (homes, hospices, long-term care facilities) treatment of TIH and MBP need to be identified and evaluated so as to guide future regional decision making.

Interventions

DRUGZoledronic acid (Zometa)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

If hypercalcemic: * Serum corrected Ca+++\>= 2.5 mmol/L and symptomatic hypercalcemia * Asymptomatic hypercalcemia with corrected Ca+++\>= 3.0 mmol/L * Moderate to severe intolerable pain (\>=6/10 on numerical rating scale \[NRS\]) despite optimal treatments with a strong opioid such as morphine, hydromorphone, fentanyl, oxycodone or methadone * Radiotherapy bone pain related to metastatic bone disease

Exclusion criteria

* Not on a regular bisphosphonate regimen

Design outcomes

Primary

Measure	Time frame
feasibility of treating hypercalcemia in the community	—
resources required	—

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026